David Kevin Imagawa

Dr. David Kevin Imagawa

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
KHKenneth Nguyen Huynh
Kenneth Nguyen Huynh
SRSriram Rao
Sriram Rao
BRBradley Roth
Bradley Roth
TBTheodore Bryan
Theodore Bryan
DFDayantha M. Fernando
Dayantha M. Fernando
NANadine Abi-Jaoudeh
Nadine Abi-Jaoudeh
Hypoxia-inducible factor 1 alpha (HIF-1α) is a transcription factor that regulates the cellular response to hypoxia and is upregulated in all types of solid tumor, leading to tumor angiogenesis, growth, and resistance to therapy. Hepatocellular carcinoma (HCC) is a highly vascular tumor, as well as a hypoxic tumor, due to the liver being a relatively hypoxic environment compared to other organs. Trans-arterial chemoembolization (TACE) and trans-arterial embolization (TAE) are locoregional therapies that are part of the treatment guidelines for HCC but can also exacerbate hypoxia in tumors, as seen with HIF-1α upregulation post-hepatic embolization. Hypoxia-activated prodrugs (HAPs) are a novel class of anticancer agent that are selectively activated under hypoxic conditions, potentially allowing for the targeted treatment of hypoxic HCC. Early studies targeting hypoxia show promising results; however, further research is needed to understand the effects of HAPs in combination with embolization in the treatment of HCC. This review aims to summarize current knowledge on the role of hypoxia and HIF-1α in HCC, as well as the potential of HAPs and liver-directed embolization.

29 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Mahmoud Kamal SingerMahmoud Kamal Singer
Mahmoud Kamal Singer
ZZZhuoli Zhang
Zhuoli Zhang
FDFarshid Dayyani
Farshid Dayyani
ZZzigeng zhang
zigeng zhang
VYVahid Yaghmai
Vahid Yaghmai
NANadine Abi-Jaoudeh
Nadine Abi-Jaoudeh
Hepatocellular carcinoma (HCC) is a major global health issue characterized by poor prognosis and complex tumor biology. One of the critical components of the HCC tumor microenvironment (TME) is tumor-associated macrophages (TAMs), which play a pivotal role in modulating tumor growth, immune evasion, and metastasis. Macrophages are divided into two major subtypes: pro-inflammatory M1 and anti-inflammatory M2, both of which may exist in TME with altered function and proportion. The anti-inflammatory M2 macrophages are further subdivided into four distinct immune suppressive subsets. TAMs are generally counted as M2-like macrophages with altered immune suppressive functions that exert a significant influence on both cancer progression and the ability of tumors to escape immune surveillance. Their involvement in modulating immune responses via different mechanisms at the local and systemic levels has made them a key target for therapeutic interventions seeking to enhance treatment outcomes. How TAMs’ depletion influences immune responses in cancer is the primary interest in cancer immunotherapies. The purpose of this review is to delve into the recent progress made in TAM-targeting therapies. We will explore the current theories, benefits, and challenges associated with TAMs’ depletion or inhibition. The manuscript concludes with future directions and potential implications for clinical practice.

22 January 2025 in Cells
Verified
Journal Article
Open access
PDF file
Mahmoud Kamal SingerMahmoud Kamal Singer
Mahmoud Kamal Singer
JVJennifer Brooke Valerin
Jennifer Brooke Valerin
ZZZhuoli Zhang
Zhuoli Zhang
ZZzigeng zhang
zigeng zhang
FDFarshid Dayyani
Farshid Dayyani
NANadine Abi-Jaoudeh
Nadine Abi-Jaoudeh
Colorectal cancer (CRC) remains one of the leading causes of cancer-related morbidity and mortality around the world. Despite advances in surgery, chemotherapy, and targeted therapies, the prognosis for patients with metastatic or advanced CRC remains poor. Immunotherapies comprising immune checkpoint inhibitors showed disappointing responses in metastatic CRC (mCRC). However, cellular immunotherapy, specifically using classical dendritic cells (cDCs), may hold unique promise in immune recognition for CRC antigens. cDCs are substantial players in immune recognition and are instrumental in orchestrating innate and adaptive immune responses by processing and presenting tumor antigens to effector cells. Natural killer T (NKT) cells are insufficiently studied but unique effector cells because of their ability to bridge innate and adaptive immune reactions and the crosstalk with dendritic cells in cancer. This review explores the therapeutic potential of using both cDCs and NKT cells as a synergistic therapy in CRC, focusing on their biological roles, strategies for harnessing their capabilities, clinical applications, and the challenges within the tumor microenvironment. Both cDCs and NKT cells can be used as a new effective approach for cell-based therapies in cancers to provide a new hope for CRC patients that are challenging to treat.

7 February 2026 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
JBJoseph A. Breuer
Joseph A. Breuer
MMMishal Mendiratta-Lala
Mishal Mendiratta-Lala
FLFred T. Lee
Fred T. Lee
ZLZain Lalani
Zain Lalani
LPLexiana Poe
Lexiana Poe
NANadine Abi-Jaoudeh
Nadine Abi-Jaoudeh

26 July 2020 in Updates in Surgery
Verified
Journal Article
Open access
PDF file
AGA. Grigorian
A. Grigorian
ADA. R. Dosch
A. R. Dosch
PDP. T. Delaplain
P. T. Delaplain
DIDavid Kevin Imagawa
David Kevin Imagawa
ZJZ. Jutric
Z. Jutric
JNJ. Nahmias
J. Nahmias
Trauma pancreaticoduodenectomy (TP) remains a challenging operation with morbidity and mortality rates as high as 80% and 50%. Many trauma surgeons consider it surgical dogma to avoid performing a TP during the index operation for patients with severe pancreatic or duodenal injuries. However, there is no modern analysis evaluating this belief. Therefore, we hypothesized no difference in risk of mortality between patients with severe pancreatic or duodenal injury undergoing a TP for penetrating trauma to propensity-matched controls undergoing laparotomy without TP. The Trauma Quality Improvement Program (2010–2016) was queried for adults with severe penetrating pancreatic or duodenal injuries undergoing laparotomy. A 1:2 propensity-matching including demographics/comorbidities, injury severity score, vitals on admission, Glasgow Coma Scale and concomitant injuries for laparotomy with or without TP was performed. Risk of mortality was reported using a univariable logistic regression model. Of 2182 patients with severe pancreatic or duodenal injuries undergoing laparotomy, 54 (2.5%) underwent TP and 2128 (97.5%) underwent laparotomy without TP. There were no differences in propensity-matching characteristics. Patients undergoing TP had a similar mortality rate (20.0% vs. 28.7%, p = 0.302) but a longer length of stay (LOS) (27.5 vs. 16.5 days, p = 0.017). The TP group had a similar associated risk of mortality (OR = 0.62, p = 0.302) but higher risk of major complications (OR 3.44, CI 1.35–17.47, p = 0.015). In appropriately selected penetrating trauma patients with severe pancreatic/duodenal injuries, TP is associated with a similar risk of mortality compared to laparotomy without TP. However, TP patients did have an increased associated risk of major complications and longer LOS.

1 August 2003 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
MSMing-Sing Si
Ming-Sing Si
DIDavid Kevin Imagawa
David Kevin Imagawa
PJPing Ji
Ping Ji
XWXunbin Wei
Xunbin Wei
BHBari Holm
Bari Holm
DBDominic C. Borie
Dominic C. Borie